Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Given Consensus Recommendation of “Hold” by Brokerages

Share on StockTwits

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has received a consensus recommendation of “Hold” from the seven analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $22.75.

A number of research firms have weighed in on PRTK. BTIG Research set a $36.00 price target on Paratek Pharmaceuticals and gave the stock a “sell” rating in a research report on Friday, November 1st. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, HC Wainwright lowered their price objective on shares of Paratek Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

In other news, CEO Evan Loh sold 7,818 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $3.82, for a total transaction of $29,864.76. Following the sale, the chief executive officer now owns 439,935 shares in the company, valued at approximately $1,680,551.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Randall B. Brenner sold 7,674 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total value of $30,542.52. Following the sale, the insider now owns 91,338 shares in the company, valued at approximately $363,525.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,079 shares of company stock valued at $145,472. Company insiders own 7.70% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTK. Vanguard Group Inc. increased its holdings in Paratek Pharmaceuticals by 45.5% during the second quarter. Vanguard Group Inc. now owns 1,602,747 shares of the specialty pharmaceutical company’s stock worth $6,394,000 after buying an additional 501,177 shares during the last quarter. General American Investors Co. Inc. increased its stake in shares of Paratek Pharmaceuticals by 59.4% during the 3rd quarter. General American Investors Co. Inc. now owns 749,660 shares of the specialty pharmaceutical company’s stock worth $3,239,000 after purchasing an additional 279,475 shares during the last quarter. Roumell Asset Management LLC increased its stake in shares of Paratek Pharmaceuticals by 3.2% during the 2nd quarter. Roumell Asset Management LLC now owns 678,795 shares of the specialty pharmaceutical company’s stock worth $2,708,000 after purchasing an additional 21,099 shares during the last quarter. State Street Corp increased its stake in shares of Paratek Pharmaceuticals by 4.9% during the 3rd quarter. State Street Corp now owns 673,779 shares of the specialty pharmaceutical company’s stock worth $2,911,000 after purchasing an additional 31,526 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Paratek Pharmaceuticals by 1.1% in the 2nd quarter. Northern Trust Corp now owns 414,364 shares of the specialty pharmaceutical company’s stock valued at $1,653,000 after purchasing an additional 4,517 shares during the period. 67.64% of the stock is owned by institutional investors.

PRTK opened at $3.06 on Monday. The company has a market capitalization of $99.86 million, a price-to-earnings ratio of -0.86 and a beta of 1.71. The business’s 50-day moving average price is $3.28 and its two-hundred day moving average price is $3.75. Paratek Pharmaceuticals has a 1 year low of $2.66 and a 1 year high of $7.39. The company has a debt-to-equity ratio of 14.48, a current ratio of 9.80 and a quick ratio of 9.45.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.06. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 505.07%. The company had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $3.63 million. Sell-side analysts anticipate that Paratek Pharmaceuticals will post -4.19 earnings per share for the current fiscal year.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Read More: What are Bollinger Bands?

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.